Hypertrophic Cardiomyopathy Lunch & Learn Series

Join us for a 4 part lunch and learn series on hypertrophic cardiomyopathy on the following days:

• Thursday, July 13
• Thursday, July 20
• Thursday, July 27
• Thursday, Aug 3

Supported by Bristol-Myers Squibb.

Learning Objectives

Hypertrophic Cardiomyopathy: Novel Treatments

1. 1. Identify characteristics of nonobstructive and obstructive HCM
   2. Describe the mechanism of action of cardiac myosin inhibitor
   3. Examine current literature and research into novel HCM treatment/s
   4. Analyze best clinical practice scenarios

Hypertrophic Cardiomyopathy: Patient Access and Team-Based Care

1. 1. Discuss access considerations for novel HCM treatments
   2. Explain potential barriers and related solutions to prescribing a cardiac myosin inhibitor, including prior authorizations and specialty pharmacy considerations
   3. Compare team-based approaches for successful medication administration in clinical setting, pharmacy, and home
   4. List the follow-up echocardiography requirements for HCM management

Hypertrophic Cardiomyopathy: Patient Adherence

1. 1. Describe the drug administration pathway from initiation to maintenance
   2. Discuss signs and symptoms that signify a needed dose adjustment
   3. Describe patient HCM treatment journey
   4. Assess team-based care scenarios for improving outcomes for patients taking novel medications

Hypertrophic Cardiomyopathy: Ask the Experts

1. 1. Review highlights of team-based care approach to ordering and administering novel HCM pharmaceutical therapy
   2. Using case-based scenarios, identify best practices for prescribing and administering novel medications for HCM
   3. Discuss how to maximize effective communications in team-based care
   4. Describe effective strategies for shared decision-making for patients with HCM and their family